Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMID in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival .
http://www.news-medical.net/news/20130711/Phase-III-study-REVLIMID-meets-primary-endpoint-in-patients-newly-diagnosed-with-multiple-myeloma.aspx
http://www.news-medical.net/news/20130711/Phase-III-study-REVLIMID-meets-primary-endpoint-in-patients-newly-diagnosed-with-multiple-myeloma.aspx
No comments:
Post a Comment